IMR Press / EJGO / Volume 30 / Issue 4 / pii/2009096

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Clinicopathological features of primary fallopian tube carcinoma: a single institution experience

Show Less
1 Department of Clinical Therapeutics, “Alexandra” Hospital, University of Athens School of Medicine(Greece)
2 Department of Pathology, “Alexandra” Hospital (Greece)
3 First Department of Obstetrics and Gynecology, “Alexandra” Hospital, University of Athens School of Medicine (Greece)
4 Hellenic Co-operative Oncology Group (HeCOG) Data Office, Athens (Greece)
Eur. J. Gynaecol. Oncol. 2009, 30(4), 389–395;
Published: 10 August 2009

Purpose of investigation: Primary fallopian tube carcinoma (PFTC) is a rare malignancy with only few data existing on the impact of prognostic factors. Methods: We retrospectively analyzed 26 patients. Tissue blocks were reviewed and sections were stained for vascular endothelial growth factor (VEGF), matrix metalloproteinases 2 and 9 (MMP-2, MMP-9), tissue inhibitors of metallopro-teinases 1 and 2 (TIMP-1, TIMP-2), c-erbB-2, estrogen (ER), and progesterone receptors (PgR). Results: Reactivity for VEGF, ER, PgR, MMP-2, MMP-9, TIMP-1, TIMP-2 and c-erbB-2 was observed in 85%, 46%, 27%, 11.5%, 58%, 0%, 23% and 8% of specimens, respectively. None of the markers studied displayed prognostic significance. Regarding clinical prognostic factors, the hazard ratio (HR) for progression and death for patients with tumor residuum >2 cm was 5.24 (p < 0.01) and 11.19 (p < 0.005), respectively. Patients with advanced stage disease had a HR of 12.55 (p < 0.05) for progression, while the HR for death was not found to be statistically significant. Conclusion: None of the biomarkers studied seems to influence survival. Early-stage disease and optimal debulking are asso-ciated with improved outcome.

Primary fallopian tube cancer
Prognostic factors
First-line chemotherapy
Back to top